Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1997-12-19
1999-06-01
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241851, 4241921, 435 697, 5303873, 530351, A61K 39395, A61K 3900, C07K 100, C07K 1600
Patent
active
059086262
ABSTRACT:
Disclosed is a hybrid recombinant protein consisting of human interferon-.beta., and a human immunoglobulin Fc fragment, preferably .gamma.4 chain, joined by a peptide linker comprising the sequence Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID NO:1).
REFERENCES:
patent: 4289689 (1981-09-01), Friesen et al.
patent: 4973478 (1990-11-01), Gauldi et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5015730 (1991-05-01), Friesen et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5428130 (1995-06-01), Capon et al.
patent: 5460811 (1995-10-01), Goeddel et al.
patent: 5468607 (1995-11-01), Revel et al.
patent: 5468608 (1995-11-01), Revel et al.
patent: 5468609 (1995-11-01), Revel et al.
*Wick, Georg, et. al; "Thymic Nurse Cells . . . "; Eur. J. Immunol.; vol. 16; 1986; pp. 855-858.
*Mustelin, Tomas, et. al; "Myo-Inasitol Reverses . . . " Eur. J. Immunol.; vol. 16; 1986; pp. 859-861.
*Haak-Frendscho, M. et. al; "Inhibition of Interferon . . . " Immunology; vol. 79, 1993; pp. 594-599.
*Knapp, W. et. al; "Towards a Better Definition . . . " 1989; pp. 253-258.
*Neuberger, Michael, et. al; "Recombinant Antibodies . . . "; Nature, vol. 312, Dec. 13, 1984 p. 604-608.
*Bennett, Brian, et. al; "Extracellular Domain . . . "; Journal of Biological Chemistry; vol. 266, No. 34, Dec. 5, 1991, pp. 23060-23067.
*Gorman, Cornelia, et. al; "Transient Production . . . "; DNA & Protein Engineering Techniques; vol 2, #1, 1990, p. 3-10.
*Cosman, David; "Expression Cloning"; DNA & Protein Engineering Techniques; vol. 2, #1, 1990, p. 1-3.
*Peppel, Karsten; "A Tumor Necrosis Factor . . . "; J. Exp. Med., vol. 174, Dec. 1991; p. 148-149.
*Mark, Melanie, et. al; "Expression & Characterization . . . "; Journal of Biological Chemistry; vol. 267, No. 36, Dec. 25, 1992; pp. 26166-26171.
*Gascoigne, Nicholas; et. al; Proc. Natl. Acad. Sci USA; vol. 84, pp. 2936-2940; May 1987.
*Scallon, Bernard; et. al; "Functional Comparisons . . . "; Cytokine, vol. 7, No. 8, Nov. 1995; pp. 759-770.
*Mariuzza, Roy, et. al; "Secretion of a . . . "; Journal of Biological Chemistry, vol. 264, No. 13, May 5, 1989, pp. 7310-7316.
*Askenazi, Avi, et. al; "Protection Against . . . "; Proc. Natl. Acad. Sci, USA; vol. 88, Dec. 1991, pp. 10535-10539.
*Traunecker, Andre, et. al; "Soluble CD4 . . . "; Nature, vol. 331, Jan. 1988, pp. 84-86.
*Munro, Alan; "Uses of Chimaeric Antibodies"; Nature, vol. 312, Dec. 13, 1984; p. 597.
*Boulianne, Gabrielle; et. al; "Production of . . . "; Nature, vol. 312, Dec. 13, 1984; pp. 643-646.
*Sharon, J., et. al; "Expression of a V.sub.H C.sub.k . . . "; Nature, vol. 309, May 24, 1984, pp. 364-367.
*Traunecker, Andre, et. al.; "Highly Efficient . . . "; Nature, vol. 339, May 4, 1989, pp. 68-70.
*Byrn, Randal, et. al; "Biological Properties . . . "; Nature, vol. 344, Apr. 12, 1990; pp. 667-670.
*Naldini, Luigi, et. al; "Scatter factor . . . "; The EMBO Journal, vol. 10, No. 10, 1991; pp. 2867-2878.
*deSauvage, Frederic, et. al; "Primary Structure . . . " Journal of Biological Chemistry; vol. 266, No. 27, Sep. 25, 1991 pp. 17912-17918.
*Morrison, Sherie; "Transfectomas Provide . . . "; Science, vol. 229, Sep. 20, 1985; pp. 1202-1207.
*Williams, Gareth; "Production of . . . "; Gene, vol. 43, 1986, pp. 319-324.
*Morrison, Sherie, et. al; "Chimeric human . . . "; Proc. Natl. Acad. Sci. USA; vol. 81, Nov., 1984; pp. 6851-6855.
*Traunecker, Andre; et. al; "A Novel Approach . . . "; Eur. J. Immunol.; vol. 16, 1986, pp. 851-854.
*Lesslauer, Werner, et. al; "Recombinant Soluble . . . " Eur. J. Immunol., vol. 21; 1991 pp. 2883-2886.
*Becker, Michael, et. al; "Expression of a . . . "; Cell; vol. 58, Sep. 8, 1989; pp. 911-921.
Huston, JS et al, Methods in Enzymology 203:46-88.
N.F. Landolfi; Chimeric IL-2/Ig Molecule J. Immunol 146:915-919 (1991).
Peterhans, A., et al., Analytical Biochemistry 163(2)470-75.
Baron, E. and Narula, S., Biotechnology, 10:179-190, 1990, From cloning to commercial realization: Human alpha interferon.
Bocci, V., Interferon, 4:47-72, 1985, Distribution, catabolism and pharmacokinetics of interferons.
Bohoslawec, O. et al., J. Interferon Res., 6:207-213, 1986, Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in Mice.
Bonetti, A. and Kim, S. Cancer Chemother Pharmacol. 33:258-261, 1993, Pharmacokinetics of an extended-release human interferon alpha-2b formulation.
Brown, K.D. Genetic Engineering News, 15:1-35, 1995, Novel emerging therapeutics target the hepatitis C virus.
Brunt, J.V., Biotechnology, 7:549, 1989, Interferon trials proliferate.
Cantell, K. et al., Methods in Enzymology, 78A:29-38, Adacemic Press, 1981.
Coligan, J.E. et al., Current protocols in immunology, pp. 6.9.1-6.9.8, Current Protocols, 1991, Measurement of antiviral activity induced by interferon .alpha., .beta., and .gamma..
Daugherty, B.L. et al., Nucleic Acids Res. 19:2471-6, 1991, Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of murine monoclonal antibody directed against the CD18 component of leukocyte integrins.
Dianzani, F. J. Interferon Res. (Special Issue) 109:118, 1992, Interferon treatments: how to use an endogenous system as a therapeutic agent.
Evinger, M. and Pestka, S., Methods in Enzymology, 79:362-8, Assay of growth inhibition in lymphoblastoid cell cultures.
Goeddel, D.V. et al., Nature, 290:20-26, 1981, The structure of eight distinct cloned human leukocyte interferon dDNAs.
Gutterman, J., Proc. Natl. Aca. Sci. 91:1198-1205;1994, Cytokine therapeutics: lessons from interferon .alpha..
Johns, T.G. et al., Cancer Res., 50:4718-23, 1990, Pharmacokinetics, tissue recombinant human and murine .alpha. interferons in mice.
Kabat, E.A. et al., Sequences of proteins of immunological interest, pp. 1582-1598, NIH, 1991.
Kurschner, C. et al., J. Immunol. 149:4096-4100, 1992, IFN-.gamma. receptor-Ig fusion proteins.
Mordenti J. et al., Nature, 337:525-31, 1989, Designing CD4 immunoadhesins for AIDS therapy.
Quesada, J.R. et al., J. Clin. Oncol. 4:234-243, 1986, Clinical toxicity of interferons in cancer patients: a review.
Roche Labs., Referon A, Schering, Intron A, Physicians' Desk Reference, 47 edition, 1993, pp. 2006-2008, 2194-2201.
Roitt. I., Essential Immunology, 7th edition, 1991, Blackwell Scientific Publications, pp. 45-51, Immunoglubulin classies and subclasses.
Saiki, R.K. et al., Science, 239:487, 1988, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Sambrook, J. et al., Molecular cloning, 1989, Cold Spring Harbor Laboratory Press, pp. 16.28-16.29.
Schein, C.H. and Noteborn, H.M., Bio/technology, 6:291-294, 1988, Formation of soluble recombinant proteins in Escherichia coli is favored by lower growth temperature.
Scorer, C.A. et al.,Gene, 136:111-9, 1993, The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast Pichia pastoris.
Strander, H. Adv. Cancer Res. 46:1-265, 1986, Interferon treatment of human neoplasia.
Tabata, Y. et al., Cancer Res. 51:5532-8, 1991, Effects of recombinant alpha-interferon-gelatin conjugate on in vivo murine tumor cell growth.
von Gabain, A., et al., Eur. J. Biochem. 190:257-61, 1990, Three human interferon-.alpha.2 subvariants disclose structural and functional differences.
Weissmann, C. and Weber, H. Prog. Nuc. Acid Res. Mol. Biol. 33:251-300, 1986, The interferon genes.
Wilkinson, D.L. and Harrison, R.G., Bio/technology, 9:443-448, 1991, Predicting the solubility of recombinant proteins in Escherichia coli.
Zoon, K.C. Interferon, 9:1-12, 1987, Human interferons: structure and function.
Chang Tse Wen
Yu Liming
Feisee Lila
Mirabel Eric P.
Tanox, Inc.
Ungar Susan
LandOfFree
Hybrid with interferon-.beta. and an immunoglobulin Fc joined by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid with interferon-.beta. and an immunoglobulin Fc joined by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid with interferon-.beta. and an immunoglobulin Fc joined by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-953546